He Mengrong, Jin Qiaofeng, Deng Cheng, Fu Wenpei, Xu Jia, Xu Lingling, Song Yishu, Wang Rui, Wang Wenyuan, Wang Lufang, Zhou Wuqi, Jing Boping, Chen Yihan, Gao Tang, Xie Mingxing, Zhang Li
Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Hubei Province Clinical Research Center for Medical Imaging, Wuhan, China; Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China.
Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Hubei Province Clinical Research Center for Medical Imaging, Wuhan, China; Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China.
Ultrasound Med Biol. 2023 Jul;49(7):1647-1657. doi: 10.1016/j.ultrasmedbio.2023.03.020. Epub 2023 Apr 27.
Acute rejection (AR) screening has always been the focus of patient management in the first several years after heart transplantation (HT). As potential biomarkers for the non-invasive diagnosis of AR, microRNAs (miRNAs) are limited by their low abundance and complex origin. Ultrasound-targeted microbubble destruction (UTMD) technique could temporarily alter vascular permeability through cavitation. We hypothesized that increasing the permeability of myocardial vessels might enhance the abundance of circulating AR-related miRNAs, thus enabling the non-invasive monitoring of AR.
The Evans blue assay was applied to determine efficient UTMD parameters. Blood biochemistry and echocardiographic indicators were used to ensure the safety of the UTMD. AR of the HT model was constructed using Brown-Norway and Lewis rats. Grafted hearts were sonicated with UTMD on postoperative day (POD) 3. The polymerase chain reaction was used to identify upregulated miRNA biomarkers in graft tissues and their relative amounts in the blood.
Amounts of six kinds of plasma miRNA, including miR-142-3p, miR-181a-5p, miR-326-3p, miR-182, miR-155-5p and miR-223-3p, were 10.89 ± 1.36, 13.54 ± 2.15, 9.84 ± 0.70, 8.55 ± 2.00, 12.50 ± 3.96 and 11.02 ± 3.47 times higher in the UTMD group than those in the control group on POD 3. Plasma miRNA abundance in the allograft group without UTMD did not differ from that in the isograft group on POD 3. After FK506 treatment, no miRNAs increased in the plasma after UTMD.
UTMD can promote the transfer of AR-related miRNAs from grafted heart tissue to the blood, allowing non-invasive early detection of AR.
急性排斥反应(AR)筛查一直是心脏移植(HT)术后最初几年患者管理的重点。作为AR无创诊断的潜在生物标志物,微小RNA(miRNA)受其低丰度和复杂来源的限制。超声靶向微泡破坏(UTMD)技术可通过空化作用暂时改变血管通透性。我们推测增加心肌血管的通透性可能会提高循环中AR相关miRNA的丰度,从而实现对AR的无创监测。
采用伊文思蓝试验确定有效的UTMD参数。利用血液生化和超声心动图指标确保UTMD的安全性。使用Brown-Norway大鼠和Lewis大鼠构建HT模型的AR。在术后第3天(POD 3)用UTMD对移植心脏进行超声处理。采用聚合酶链反应鉴定移植组织中上调的miRNA生物标志物及其在血液中的相对含量。
在POD 3时,UTMD组血浆中miR-142-3p、miR-181a-5p、miR-326-3p、miR-182、miR-155-5p和miR-223-3p这六种血浆miRNA的含量分别比对照组高10.89±1.36倍、13.54±2.15倍、9.84±0.70倍、8.55±2.00倍、12.50±3.96倍和11.02±3.47倍。未进行UTMD的同种异体移植组血浆miRNA丰度在POD 3时与同基因移植组无差异。FK506治疗后,UTMD后血浆中没有miRNA增加。
UTMD可促进AR相关miRNA从移植心脏组织向血液的转移,从而实现AR的无创早期检测。